Detection & Characterization of Sessile Serrated Lesions (SSL) of

Status Active, not recruiting

Clinical Trial Summary

There are a few studies regarding Sessile Serrated Lesions (SSL). They are recently identified as precancerous lesions. Yet, digestive tract serrated lesions would be part of a new colic carcinogenesis way : the serrated tumor way. Evolution from polyp to cancer would be faster than through the usual adenoma to cancer way. It would be then responsible of a lot of "missed" lesions or interval cancer. The missed SSL rate is estimated at between 27% and 59%. Current diagnosis methods show weakness to identify those SSL. In order to improve their detection, the investigators dispose of several coloration techniques. Indigo carmine chromoendoscopy enhance neoplastic lesion detection as part of the hereditary rectal carcinoma screening. NBI electronic coloration, which is faster and easier has not shown any efficacy on the adenoma detection rate, except for patients with Lynch syndrome. The objective is to better describe the SSL endoscopic semiology (detection and characterization) and to establish standards for the endoscopic techniques in order to improve the colonoscopy diagnosis quality. The investigators propose to evaluate 2 fundamental endoscopic techniques (Narrow Band Imaging (NBI) and indigo carmine), widely used for other indications, in comparison with the White Light technique (WLI). Therefore, the investigators propose a prospective, observational, multicentric cohort study in order to 1) define SSL endoscopic various aspects 2) establish which technique (white light, Narrow Band Imaging, indigo carmine chromoendoscopy) is the best to diagnose SSL, namely detection and characterization 3) evaluate the multifocal dimension rate for those lesions at ascending colon level. The diagnosis impact is immediate, and could allow to consider an update for boh endoscopic NICE and Kudo Pit Pattern classification, and good practice guidances for colonoscopic diagnosis. Better SSL detectability thus their systematic resection could have a long term effect in reducing both colon cancer rate and interval cancer

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02861885
Study type	Observational
Source	Hospices Civils de Lyon
Contact
Status	Active, not recruiting
Phase
Start date	February 24, 2016
Completion date	April 24, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03826043` - THrombo-Embolic Event in Onco-hematology	N/A
Terminated	`NCT03166631` - A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread	Phase 1
Completed	`NCT01938846` - BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors	Phase 1
Recruiting	`NCT06058312` - Individual Food Preferences for the Mediterranean Diet in Cancer Patients	N/A
Completed	`NCT03308942` - Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants	Phase 2
Recruiting	`NCT06018311` - Exercising Together for Hispanic Prostate Cancer Survivor-Caregiver Dyads	N/A
Withdrawn	`NCT05431439` - Omics of Cancer: OncoGenomics
Completed	`NCT01343043` - A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma	Phase 1
Completed	`NCT01938638` - Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer	Phase 1
Recruiting	`NCT05514444` - Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001)	Phase 1
Recruiting	`NCT02292641` - Beyond TME Origins	N/A
Terminated	`NCT00954512` - Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)	Phase 1/Phase 2
Recruiting	`NCT04958239` - A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors)	Phase 1
Recruiting	`NCT04627376` - Multimodal Program for Cancer Related Cachexia Prevention	N/A
Completed	`NCT01222728` - Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients
Recruiting	`NCT06004440` - Real World Registry for Use of the Ion Endoluminal System
Active, not recruiting	`NCT05636696` - COMPANION: A Couple Intervention Targeting Cancer-related Fatigue	N/A
Not yet recruiting	`NCT06035549` - Resilience in East Asian Immigrants for Advance Care Planning Discussions	N/A
Recruiting	`NCT06004466` - Noninvasive Internal Jugular Venous Oximetry
Completed	`NCT03190811` - Anti-PD-1 Alone or Combined With Autologous DC-CIK Cell Therapy in Advanced Solid Tumors	Phase 1/Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Detection and Characterization of Sessile Serrated Lesions (SSL) of the Right Colon — Lesion SSL

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms